Porosome Therapeutics, Inc. Announces Positive Results in Animal Studies for Treatment of Cystic Fibrosis

April 15, 2024 (BOSTON) Porosome Therapeutics, Inc. (Porosome Therapeutics) today announced that initial animal studies have provided further validation of the company’s groundbreaking approach for the treatment of cystic fibrosis (CF). The company presented their findings during the April 2024 American Physiological Society’s Summit in Long Beach, California, highlighting the potential of porosome reconstitution therapy to restore normal chloride conduction. Previous preclinical studies indicated the Company’s treatment regimen overcomes CF nearly four times more effectively than currently available medications to treat the inherited disorder.

“Porosomes obtained from functional WT-CFTR human bronchial epithelial cells were used to treat the nasal passages of CF-affected mice,” said Professor Bhanu P. Jena, Founder and Chairman, Porosome Therapeutics. “Remarkably, within 24 hours of treatment, this reconstitution of the porosome rescued chloride secretion in the nasal passage. We are diligently conducting further studies to comprehensively assess the safety, stability, and optimal dosage of this approach.”

The Company’s groundbreaking approach successfully restored normal chloride conduction and further demonstrated that the porosome can properly function within cross species without triggering an immune rejection.

“These new results mark a major breakthrough in our efforts to find a path to a cure, not only for CF but for a wide range of debilitating diseases and chronic conditions,” said Guillermo Marmol, CEO, Porosome Therapeutics. “We are celebrating this milestone, but our focus remains on the preparation for our upcoming clinical studies.”

Almost three decades ago, Professor Bhanu P. Jena discovered a new cellular structure called the porosome, which serves as the universal gateway for secretion within cells. After the revolutionary discovery, the porosome was isolated and its structure and composition determined before porosomes were successfully inserted (reconstituted) into cells to correct secretory defects.

The continuation of this research will lay the groundwork for treating CF and various other secretory disorders such as diabetes, Alzheimer’s, and specific cancers. The novel approach provides an historic opportunity to target undruggable proteins, which make up almost 85% of the human proteome.

About Porosome Therapeutics, Inc.

Porosome Therapeutics, Inc. is a Boston-based biopharmaceutical company utilizing breakthrough discovery and novel technologies to identify and create patent-pending high-value therapeutics for currently undruggable porosome proteins and lipid targets relating to secretory and hydration disorders such as cystic fibrosis, diabetes, and cancer. It is the first company with a technology platform that develops novel therapies targeting the porosome, the universal secretory machinery in cells. This platform is based on decades of research supported by more than 200 publications and is effective against many serious diseases involving secretory defects. The platform also specializes in highly specific nanobody-mediated targeted therapies that greatly reduce drug side effects.

BioMediaHub Logo
BioMediaHub Logo